A recent study suggests that the relationship between coffee consumption and the risk of developing Parkinson's disease may depend on an individual's genetic profile for caffeine metabolism. Research published in the journal Parkinson’s Disease analyzed data from over 435,000 participants in the UK Biobank and found that while there was no overall link across the entire population, distinct patterns emerged when people were grouped by their genetic ability to process caffeine.
The investigation, which followed participants for a median of 15.7 years, focused on a common variation in the CYP1A2 gene, which governs how the liver breaks down caffeine. For individuals classified as fast caffeine metabolizers, consuming fewer than five cups of coffee daily was associated with a 17% reduced risk of the disease compared to non-coffee drinkers, with the most significant benefit observed at around three cups per day.
Conversely, the outcome was different for those with slower caffeine metabolism. In this group, consuming five or more cups daily was associated with a 43% to 84% increased risk of developing Parkinson's. These findings may help explain why previous studies on the topic have produced inconsistent results. The authors noted the study was observational and relied on self-reported coffee intake at a single point in time, without distinguishing between caffeinated and decaffeinated varieties.